Mani Foroohar

Moderna, Inc. (NASDAQ: MRNA) shares were solidly higher in premarket trading on Wednesday. What Happened: The upside in Moderna’s shares comes in reaction to a clinical readout announced late Tuesday, which showed that the Cambridge, Massachusetts-based company’s mRNA vaccine targeting...

Moderna, Inc. (NASDAQ: MRNA) reported better-than-expected fourth-quarter earnings Thursday and announced a slight upward revision to its vaccine sales forecast for 2022. The company also announced a $3-billion stock buyback. The stock rallied 15.1% in Thursday's trading session. Here's...

An SVB Leerink genetic medicine analyst is bullish on shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA). Here's why.  The Intellia Analyst: SVB Leerink analyst Mani Foroohar, M.D. reiterated an Outperform rating on Intellia and increased his price target from $81 to $159. The Intellia...

Moderna Inc's (NASDAQ: MRNA) coronavirus vaccine candidate, mRNA-1273, got FDA panel backing, in line with expectations, and is likely to be accorded emergency use authorization any time now. An Unsurprising Decision: The 20-0 vote, with one abstention, in favor of issuing an EUA for mRNA-1273...

Moderna Inc (NASDAQ: MRNA) announced Monday positive efficacy data from the first interim analysis of the Phase 3 COVE study of its investigational coronavirus vaccine mRNA-1273. The Moderna Analysts: SVB Leerink analyst Mani Foroohar maintained an Underperform rating on Moderna. Needham analyst...

Moderna Inc (NASDAQ: MRNA) shares were advancing strongly Monday after a rival vaccine developed by Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR (NASDAQ: BNTX) showed efficacy in a late-stage study. High Bar For Moderna To Clear: The 90% vaccine efficacy demonstrated by Pfizer and...

Moderna Inc (NASDAQ: MRNA) reported mixed quarterly results Thursday and suggested an interim efficacy readout from the Phase 3 study is likely in November. The Moderna Bull Case: Moderna's vaccine timeline is intact, according to Needham analyst Alan Carr, who rates the shares a Buy...

Moderna Inc (NASDAQ: MRNA) is one of the frontrunners in a crowded race to develop a vaccine against the novel coronavirus. Despite Moderna's strong positioning, an analyst at SVB Leerink said he harbors some concerns over the company's vaccine program. The Moderna Analyst: Mani...

Coronavirus vaccine developer Moderna Inc (NASDAQ: MRNA) held a virtual R&D event Thursday, showcasing its portfolio and key therapeutic areas. The Moderna Analysts: Chardan analyst Geulah Livshits has a Buy rating on Moderna with a $95 price target.  SVB Leerink analyst Mani...

Moderna Inc (NASDAQ: MRNA) shares, which shed over 13% Tuesday on an analyst downgrade, are reversing course — with a competitor's clinical woes as the catalyst. The Moderna Analyst: SVB Leerink analyst Mani Foroohar has a Neutral rating on Moderna with a $41 price target. ...

Competitive pressure could impair Moderna Inc's (NASDAQ: MRNA) ability to take advantage of its strong position in the coronavirus vaccine race, according to an analyst at SVB Leerink. The Moderna Analyst: Mani Foroohar downgraded Moderna from Market Perform to Underperform and lowered the...

Two Moderna Inc (NASDAQ: MRNA) analysts issued snapshots this week on the progress of the company's coronavirus vaccine program. The Moderna Analysts: SVB Leerink analyst Mani Foroohar maintained a Market Perform rating on Moderna with a $58 price target.  Morgan Stanley analyst...

After hinting at ongoing negotiations for larger vaccine deals on its earnings call, Moderna Inc (NASDAQ: MRNA) said late Tuesday that it signed an agreement with the U.S. government to supply 100 million doses of its coronavirus vaccine candidate mRNA-1273 for $1.525 billion. The Moderna...

Moderna Inc (NASDAQ: MRNA) shares were moving to the downside Wednesday despite the coronavirus vaccine developer reporting forecast-beating second-quarter results and reports of a potential deal with the Swiss government. Moderna's Q2 Report: Cambridge, Massachusetts-based Moderna said...

Close on the heels of announcing additional BARDA funding for its coronavirus vaccine candidate mRNA-1273, Moderna Inc (NASDAQ: MRNA) said Monday that it has commenced a late-stage study of the investigational vaccine in collaboration with the NIH and the BARDA. Moderna Sticks With July...